Management of gastrointestinal (GI) toxicity associated with nivolumab (NIVO) plus ipilimumab (IPI) or IPI alone in phase II and III trials in advanced melanoma (MEL).

被引：10

作者：

Weber, Jeffrey S.

Larkin, James M. G.

Schadendorf, Dirk

Wolchok, Jedd D.

Wagstaff, John

Dummer, Reinhard

Hogg, David

Guidoboni, Massimo

Sosman, Jeffrey Alan

Chmielowski, Bartosz

Gerritsen, Winald

Bhore, Rafia

Walker, Dana

Gonzalez, Rene

机构：

[1] NYU, Langone Med Ctr, Laura & Isaac Perlmutter Canc Ctr, New York, NY USA

[2] Royal Marsden Hosp, London, England

[3] Univ Hosp Essen, Essen, Germany

[4] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[5] Singleton Hosp, South West Wales Canc Inst, Swansea, W Glam, Wales

[6] Swansea Univ Coll Med, Swansea, W Glam, Wales

[7] Univ Zurich, Dermatol Klin, Zurich, Switzerland

[8] Princess Margaret Hosp, Toronto, ON, Canada

[9] Ist Sci Romagnolo Studio & Cura Tumori IRST IRCCS, Meldola, Italy

[10] Northwestern Univ, Med Ctr, Chicago, IL 60611 USA

[11] Univ Calif Los Angeles, Hematol Oncol Outpatient Clin, Los Angeles, CA USA

[12] Radboud Univ Nijmegen Med Ctr, Nijmegen, Netherlands

[13] Bristol Myers Squibb Co, Princeton, NJ USA

[14] Univ Colorado, Comprehens Canc Ctr, Denver, CO 80202 USA

来源：

关键词：

D O I：

10.1200/JCO.2017.35.15_suppl.9523

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

9523

引用

页数：5